PAMP
CRNX icon

Polar Asset Management Partners’s Crinetics Pharmaceuticals CRNX Stock Holding History

Polar Asset Management Partners’s Portfolio CRNX Stock Details CRNX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-205,100
Closed -$3.83M – 1417
2022
Q2 		$3.83M Buy
+205,100
New +$4.09M 0.04% 570

Other funds holding CRNX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Polar Asset Management Partners's CRNX Position: Q3 2022 in Review

Polar Asset Management Partners sold out of Crinetics Pharmaceuticals (CRNX) in Q3 2022, closing a stake of 205,100 shares — an estimated $3.83M sold.

Polar Asset Management Partners first reported a position in CRNX in Q2 2022 and held it in 1 quarter. The position peaked at $3.83M in Q2 2022. 122 funds tracked by Wall St. Rank hold CRNX as of Q3 2022.

  • Polar Asset Management Partners reported no remaining Crinetics Pharmaceuticals position as of Q3 2022 after selling out during the quarter.
  • Polar Asset Management Partners sold 205,100 Crinetics Pharmaceuticals shares in Q3 2022, an estimated $3.83M.
  • Polar Asset Management Partners first reported a position in Crinetics Pharmaceuticals in Q2 2022 and held it in 1 quarter.
  • Polar Asset Management Partners's Crinetics Pharmaceuticals position peaked at $3.83M in Q2 2022.
  • 122 funds tracked by Wall St. Rank held Crinetics Pharmaceuticals as of Q3 2022.

Based on Polar Asset Management Partners's 13F filing for Q3 2022, filed 14 Nov 2022.